The Zacks Analyst Blog Highlights Mastercard, AstraZeneca and Sandisk

What happened: Zacks featured Mastercard, AstraZeneca and Sandisk in its Analyst Blog, drawn from roughly 70 reports published that day. Key numbers: Mastercard shares +7.2% versus -5.2% for the Zacks Financial Transaction Services industry over the past year. AstraZeneca -7.2% versus +7.5% for the Medical - Biomedical and Genetics industry. Why it matters: Zacks rates Mastercard Neutral on competitive pricing pressure and premium valuation, AstraZeneca on patent expiries and pipeline setbacks, and Sandisk Outperform on AI-driven enterprise SSD demand and contracted business gains. Market: +4.4% today ($168.68), -6.9% YTD, 0.2x vol — as of 13:48 UTC

Zacks featured Mastercard, AstraZeneca and Sandisk in its Analyst Blog, drawn from roughly 70 reports published that day.

Zacks rates Mastercard Neutral on competitive pricing pressure and premium valuation, AstraZeneca on patent expiries and pipeline setbacks, and Sandisk Outperform on AI-driven enterprise SSD demand and contracted business gains. Market: +4.4% today ($168.68), -6.9% YTD, 0.2x vol — as of 13:48 UTC